JP Morgan Maintains Overweight on Viking Therapeutics, Lowers Price Target to $65

Benzinga Newsdesk www.benzinga.com Negative 81.5%

Neg 81.5% Neu 0% Pos 0%

JP Morgan analyst Hardik Parikh maintains Viking Therapeutics (NASDAQ:VKTX) with a Overweight and lowers the price target from $75 to $65.